Dave Hava

David (Dave) Hava, Ph.D., is an accomplished biotech entrepreneur with nearly two decades of experience advancing innovative therapies across rare, inflammatory, metabolic, respiratory, and oncologic diseases. He brings deep expertise in drug delivery and complex product development, with a proven track record of translating novel science into clinical-stage programs.

‍

Prior to Alltrna, Dave served as Entrepreneur-in-Residence at Mass General Brigham Ventures (MGBV), where he was a founding CEO of a stealth startup and provided scientific expertise and leadership for new company formation efforts and existing companies in the MGBV portfolio. Previous to that, he was Chief Scientific Officer (CSO) and Head of Research and Development at Synlogic, where he led the discovery and development of first-in-class engineered bacterial medicines and advanced a drug candidate for the treatment of phenylketonuria from nomination to Phase 2 and subsequently launched a global Phase 3 study. Earlier in his career, he held CSO roles at Pulmatrix Inc. and Metera Pharmaceuticals, companies advancing inhaled small molecule therapies for serious respiratory diseases.

‍

Dave received his Ph.D. in molecular biology and microbiology from Tufts University and completed postdoctoral training at Brigham and Women’s Hospital and Harvard Medical School. He is an inventor on multiple patents and author of more than 40 peer-reviewed publications.